Which has stronger earnings & valuation, OGN or HELP?

Organon & Co. has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organon & Co. $6.22B 0.58 $187M $0.77 17.84 Cybin N/A N/A -$148M -$3.02 N/A

Is OGN or HELP more profitable?

Organon & Co. has a net margin of 3.41% compared to Cybin's net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Organon & Co. 3.41% 88.97% 6.03% Cybin N/A -71.78% -64.81%

Does the media refer more to OGN or HELP?

In the previous week, Cybin had 5 more articles in the media than Organon & Co.. MarketBeat recorded 9 mentions for Cybin and 4 mentions for Organon & Co.. Cybin's average media sentiment score of 1.04 beat Organon & Co.'s score of 0.68 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HELP or ARQT?

In the previous week, Cybin had 5 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 9 mentions for Cybin and 4 mentions for Arcutis Biotherapeutics. Cybin's average media sentiment score of 1.04 beat Arcutis Biotherapeutics' score of 0.44 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HELP or TARS?

In the previous week, Cybin had 6 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 9 mentions for Cybin and 3 mentions for Tarsus Pharmaceuticals. Cybin's average media sentiment score of 1.04 beat Tarsus Pharmaceuticals' score of 0.00 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend HELP or RGC?

Cybin presently has a consensus price target of $46.33, suggesting a potential upside of 296.01%. Given Cybin's stronger consensus rating and higher possible upside, equities research analysts clearly believe Cybin is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, HELP or RGC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$148M -$3.02 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is HELP or RGC more profitable?

Regencell Bioscience's return on equity of 0.00% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -71.78% -64.81% Regencell Bioscience N/A N/A N/A

Does the media prefer HELP or RGC?

In the previous week, Cybin had 8 more articles in the media than Regencell Bioscience. MarketBeat recorded 9 mentions for Cybin and 1 mentions for Regencell Bioscience. Cybin's average media sentiment score of 1.04 beat Regencell Bioscience's score of 0.00 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend HELP or MOR?

Cybin currently has a consensus price target of $46.33, indicating a potential upside of 296.01%. Given Cybin's stronger consensus rating and higher probable upside, equities analysts clearly believe Cybin is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is HELP or MOR more profitable?

Cybin has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Cybin's return on equity of -71.78% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -71.78% -64.81% MorphoSys -226.79% -694.31% -22.55%

Cybin (HELP) Competitors

$11.42 -0.28 (-2.39%)

Closing price 04:00 PM Eastern

Extended Trading

$11.51 +0.09 (+0.79%)

As of 06:53 PM Eastern

Compare

HELP vs. OGN, ARQT, TARS, RGC, and MOR

Should you buy Cybin stock or one of its competitors? Cybin's main competitors and comparable companies include Organon & Co. (OGN), Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), Regencell Bioscience (RGC), and MorphoSys (MOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cybin compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Cybin (NASDAQ:HELP) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

In the previous week, Cybin had 5 more articles in the media than Organon & Co.. MarketBeat recorded 9 mentions for Cybin and 4 mentions for Organon & Co.. Cybin's average media sentiment score of 1.04 beat Organon & Co.'s score of 0.68 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. currently has a consensus target price of $11.40, suggesting a potential downside of 17.01%. Cybin has a consensus target price of $46.33, suggesting a potential upside of 296.01%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Cybin	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Cybin has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Organon & Co. has a net margin of 3.41% compared to Cybin's net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Cybin	N/A	-71.78%	-64.81%

Organon & Co. has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.84
Cybin	N/A	N/A	-$148M	-$3.02	N/A

Summary

Organon & Co. beats Cybin on 9 of the 15 factors compared between the two stocks.

How does Cybin compare to Arcutis Biotherapeutics?

Cybin (NASDAQ:HELP) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

17.9% of Cybin shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Cybin had 5 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 9 mentions for Cybin and 4 mentions for Arcutis Biotherapeutics. Cybin's average media sentiment score of 1.04 beat Arcutis Biotherapeutics' score of 0.44 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cybin presently has a consensus price target of $46.33, suggesting a potential upside of 296.01%. Arcutis Biotherapeutics has a consensus price target of $35.57, suggesting a potential upside of 41.38%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Arcutis Biotherapeutics has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Arcutis Biotherapeutics	$376.07M	8.41	-$16.14M	$0.21	119.81

Cybin has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Cybin's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Summary

Arcutis Biotherapeutics beats Cybin on 8 of the 14 factors compared between the two stocks.

How does Cybin compare to Tarsus Pharmaceuticals?

Cybin (NASDAQ:HELP) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Tarsus Pharmaceuticals has higher revenue and earnings than Cybin. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Tarsus Pharmaceuticals	$451.36M	7.10	-$66.42M	-$1.09	N/A

Cybin currently has a consensus target price of $46.33, suggesting a potential upside of 296.01%. Tarsus Pharmaceuticals has a consensus target price of $100.86, suggesting a potential upside of 38.16%. Given Cybin's stronger consensus rating and higher probable upside, equities analysts clearly believe Cybin is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tarsus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Cybin has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

Cybin has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

17.9% of Cybin shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cybin had 6 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 9 mentions for Cybin and 3 mentions for Tarsus Pharmaceuticals. Cybin's average media sentiment score of 1.04 beat Tarsus Pharmaceuticals' score of 0.00 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cybin and Tarsus Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Cybin compare to Regencell Bioscience?

Cybin (NASDAQ:HELP) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Cybin presently has a consensus price target of $46.33, suggesting a potential upside of 296.01%. Given Cybin's stronger consensus rating and higher possible upside, equities research analysts clearly believe Cybin is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

17.9% of Cybin shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Regencell Bioscience's return on equity of 0.00% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Regencell Bioscience	N/A	N/A	N/A

Cybin has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

In the previous week, Cybin had 8 more articles in the media than Regencell Bioscience. MarketBeat recorded 9 mentions for Cybin and 1 mentions for Regencell Bioscience. Cybin's average media sentiment score of 1.04 beat Regencell Bioscience's score of 0.00 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cybin beats Regencell Bioscience on 7 of the 11 factors compared between the two stocks.

How does Cybin compare to MorphoSys?

Cybin (NASDAQ:HELP) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Cybin currently has a consensus price target of $46.33, indicating a potential upside of 296.01%. Given Cybin's stronger consensus rating and higher probable upside, equities analysts clearly believe Cybin is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cybin has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Cybin's return on equity of -71.78% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
MorphoSys	-226.79%	-694.31%	-22.55%

In the previous week, Cybin had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for Cybin and 0 mentions for MorphoSys. Cybin's average media sentiment score of 1.04 beat MorphoSys' score of 0.00 indicating that Cybin is being referred to more favorably in the media.

Company	Overall Sentiment
Cybin	Positive
MorphoSys	Neutral

Cybin has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Cybin has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

17.9% of Cybin shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cybin beats MorphoSys on 11 of the 15 factors compared between the two stocks.

Get Cybin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HELP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HELP vs. The Competition

Export

Metric	Cybin	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$908.46M	$12.12B	$7.17B	$13.38B
Dividend Yield	N/A	2.65%	2.53%	17.32%
P/E Ratio	-3.78	799.72	274.64	26.20
Price / Sales	N/A	755.20	608.57	90.53
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	2.54	10.68	11.26	6.40
Net Income	-$148M	$2.83B	$3.49B	$381.07M
7 Day Performance	-9.29%	-2.20%	-1.68%	-0.65%
1 Month Performance	-6.55%	-6.54%	-5.97%	-4.51%
1 Year Performance	N/A	-4.52%	8.11%	1.82%

Cybin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HELP Cybin	4.4854 of 5 stars	$11.42 -2.4%	$46.33 +305.7%	N/A	$908.46M	N/A	N/A	100	Positive News Analyst Downgrade
OGN Organon & Co.	1.3962 of 5 stars	$13.75 +0.1%	$11.40 -17.1%	+24.6%	$3.61B	$6.22B	17.85	10,000
ARQT Arcutis Biotherapeutics	3.8211 of 5 stars	$26.75 -2.1%	$35.57 +33.0%	+26.3%	$3.44B	$376.07M	127.39	354
TARS Tarsus Pharmaceuticals	3.1933 of 5 stars	$76.69 -0.2%	$100.86 +31.5%	+12.0%	$3.37B	$451.36M	N/A	50
RGC Regencell Bioscience	0.2789 of 5 stars	$6.20 flat	N/A	-60.1%	$3.07B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HELP) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cybin (HELP) Competitors

HELP vs. OGN, ARQT, TARS, RGC, and MOR

How does Cybin compare to Organon & Co.?

Summary

How does Cybin compare to Arcutis Biotherapeutics?

Summary

How does Cybin compare to Tarsus Pharmaceuticals?

Summary

How does Cybin compare to Regencell Bioscience?

Summary

How does Cybin compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cybin (HELP) Competitors

HELP vs. OGN, ARQT, TARS, RGC, and MOR

How does Cybin compare to Organon & Co.?

Does the media refer more to OGN or HELP?

Do analysts prefer OGN or HELP?

Do institutionals & insiders hold more shares of OGN or HELP?

Which has more volatility and risk, OGN or HELP?

Is OGN or HELP more profitable?

Which has stronger earnings & valuation, OGN or HELP?

Summary

How does Cybin compare to Arcutis Biotherapeutics?

Do insiders & institutionals hold more shares of HELP or ARQT?

Does the media refer more to HELP or ARQT?

Do analysts prefer HELP or ARQT?

Which has better valuation & earnings, HELP or ARQT?

Which has more risk & volatility, HELP or ARQT?

Is HELP or ARQT more profitable?

Summary

How does Cybin compare to Tarsus Pharmaceuticals?

Which has higher valuation and earnings, HELP or TARS?

Do analysts prefer HELP or TARS?

Is HELP or TARS more profitable?

Which has more risk and volatility, HELP or TARS?

Do insiders and institutionals hold more shares of HELP or TARS?

Does the media refer more to HELP or TARS?

Summary

How does Cybin compare to Regencell Bioscience?

Do analysts recommend HELP or RGC?

Which has stronger earnings and valuation, HELP or RGC?

Do institutionals & insiders believe in HELP or RGC?

Is HELP or RGC more profitable?

Which has more volatility & risk, HELP or RGC?

Does the media prefer HELP or RGC?

Summary

How does Cybin compare to MorphoSys?

Do analysts recommend HELP or MOR?

Is HELP or MOR more profitable?

Does the media refer more to HELP or MOR?

Which has preferable earnings & valuation, HELP or MOR?

Which has more risk and volatility, HELP or MOR?

Do institutionals and insiders have more ownership in HELP or MOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools